Larimar Therapeutics Statistics
Total Valuation
LRMR has a market cap or net worth of $395.61 million. The enterprise value is $244.30 million.
| Market Cap | 395.61M |
| Enterprise Value | 244.30M |
Important Dates
The next estimated earnings date is Wednesday, November 4, 2026, before market open.
| Earnings Date | Nov 4, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
LRMR has 104.38 million shares outstanding. The number of shares has increased by 40.23% in one year.
| Current Share Class | 103.88M |
| Shares Outstanding | 104.38M |
| Shares Change (YoY) | +40.23% |
| Shares Change (QoQ) | +15.65% |
| Owned by Insiders (%) | 1.16% |
| Owned by Institutions (%) | 48.86% |
| Float | 57.90M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | 13.08 |
| PB Ratio | 3.11 |
| P/TBV Ratio | 3.11 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 4.70, with a Debt / Equity ratio of 0.04.
| Current Ratio | 4.70 |
| Quick Ratio | 4.58 |
| Debt / Equity | 0.04 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -139.63% and return on invested capital (ROIC) is -87.12%.
| Return on Equity (ROE) | -139.63% |
| Return on Assets (ROA) | -70.96% |
| Return on Invested Capital (ROIC) | -87.12% |
| Return on Capital Employed (ROCE) | -136.49% |
| Weighted Average Cost of Capital (WACC) | 8.26% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$2.43M |
| Employee Count | 71 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -7.11% in the last 52 weeks. The beta is 0.75, so LRMR's price volatility has been lower than the market average.
| Beta (5Y) | 0.75 |
| 52-Week Price Change | -7.11% |
| 50-Day Moving Average | 3.98 |
| 200-Day Moving Average | 3.95 |
| Relative Strength Index (RSI) | 44.25 |
| Average Volume (20 Days) | 999,164 |
Short Selling Information
The latest short interest is 13.72 million, so 13.15% of the outstanding shares have been sold short.
| Short Interest | 13.72M |
| Short Previous Month | 13.44M |
| Short % of Shares Out | 13.15% |
| Short % of Float | 23.70% |
| Short Ratio (days to cover) | 13.08 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -178.99M |
| Pretax Income | -172.61M |
| Net Income | -172.61M |
| EBITDA | -178.69M |
| EBIT | -178.99M |
| Earnings Per Share (EPS) | -$1.93 |
Balance Sheet
The company has $156.27 million in cash and $4.96 million in debt, with a net cash position of $151.31 million or $1.45 per share.
| Cash & Cash Equivalents | 156.27M |
| Total Debt | 4.96M |
| Net Cash | 151.31M |
| Net Cash Per Share | $1.45 |
| Equity (Book Value) | 127.38M |
| Book Value Per Share | 1.22 |
| Working Capital | 126.51M |
Cash Flow
In the last 12 months, operating cash flow was -$155.92 million and capital expenditures -$153,000, giving a free cash flow of -$156.08 million.
| Operating Cash Flow | -155.92M |
| Capital Expenditures | -153,000 |
| Depreciation & Amortization | 301,000 |
| Net Borrowing | n/a |
| Free Cash Flow | -156.08M |
| FCF Per Share | -$1.50 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
LRMR does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -40.23% |
| Shareholder Yield | -40.23% |
| Earnings Yield | -43.63% |
| FCF Yield | -39.45% |
Analyst Forecast
The average price target for LRMR is $14.40, which is 279.95% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $14.40 |
| Price Target Difference | 279.95% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 11 |
| Revenue Growth Forecast (3Y) | n/a |
| EPS Growth Forecast (3Y) | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 1 |